Hridayesh Prakash
Overview
Explore the profile of Hridayesh Prakash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chettri D, Satapathy B, Yadav R, Uttam V, Jain A, Prakash H
Front Immunol
. 2025 Jan;
15:1532833.
PMID: 39877364
No abstract available.
2.
Mendiratta M, Mendiratta M, Ganguly S, Rai S, Gupta R, Kumar L, et al.
Stem Cell Res Ther
. 2024 Oct;
15(1):381.
PMID: 39468660
Background: Mesenchymal stem cells (MSCs) have emerged as promising candidates for immune modulation in various diseases that are associated with dysregulated immune responses like Graft-versus-Host-Disease (GVHD). MSCs are pleiotropic and...
3.
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav R, Khatkar R, Yap K, Kang C, Lyu J, Singh R, et al.
Cell Death Discov
. 2024 Sep;
10(1):414.
PMID: 39343796
Lung cancer is a severe challenge to the health care system with intrinsic resistance to first and second-line chemo/radiotherapies. In view of the sterile environment of lung cancer, several immunotherapeutic...
4.
Uttam V, Kapoor H, Rana M, Yadav R, Prakash H, Jain M, et al.
Cancer Inform
. 2024 Sep;
23:11769351241276757.
PMID: 39282627
Objectives: Aim of this study was to explore the immune-related lncRNAs having prognostic role and establishing risk score model for better prognosis and immunotherapeutic coherence for esophageal cancer (EC) patients....
5.
Mendiratta M, Mendiratta M, Mohanty S, Sahoo R, Prakash H
Int Rev Immunol
. 2023 Aug;
43(2):95-112.
PMID: 37639700
Mesenchymal Stromal/Stem Cells (MSCs) are multipotent, non-hematopoietic progenitor cells with a wide range of immune modulation and regenerative potential which qualify them as a potential component of cell-based therapy for...
6.
Kaushal A, Kaur N, Sharma S, Sharma A, Kala D, Prakash H, et al.
Vaccines (Basel)
. 2022 Dec;
10(12).
PMID: 36560548
Early and effective diagnosis of cancer is decisive for its proper management. In this context biomarker-based cancer diagnosis is budding as one of the promising ways for early detection, disease...
7.
Mishra A, Pathak Y, Mishra S, Prakash H, Tripathi V
Eur J Pharmacol
. 2022 Nov;
938:175412.
PMID: 36427534
Cancer stem cells (CSCs) are indispensable for development, progression, drug resistance, and tumor metastasis. Current cancer-directed interventions target targeting rapidly dividing cancer cells and slow dividing CSCs, which are the...
8.
Sharma U, Tuli H, Uttam V, Choudhary R, Sharma B, Sharma U, et al.
Pharmacol Res
. 2022 Nov;
186:106523.
PMID: 36377125
Despite advanced clinical and translational oncology research, mortality rates are still increasing worldwide. Recently, a class of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular...
9.
Mohammed S, Saini R, Jha A, Hadda V, Singh A, Prakash H
Front Immunol
. 2022 Oct;
13:1003384.
PMID: 36189241
No abstract available.
10.
Chauhan A, Islam A, Prakash H, Singh S
J Pharm Anal
. 2022 Jul;
12(3):394-405.
PMID: 35811622
Nuclear factor κB (NF-κB) is a ubiquitous regulator of the signalome and is indispensable for various biological cell functions. NF-κB consists of five transcription factors that execute both cytoplasmic and...